1. Role of DPP-4 and SGLT2 Inhibitors Connected to Alzheimer Disease in Type 2 Diabetes Mellitus
   A Young Sim et al, 2021, Frontiers in Neuroscience CrossRef
2. Deciphering the Role of WNT Signaling in Metabolic Syndrome–Linked Alzheimer’s Disease
   Abuzer Ali et al, 2020, Molecular Neurobiology CrossRef
3. Link between Diabetes and Alzheimer’s Disease Due to the Shared Amyloid Aggregation and Deposition Involving Both Neurodegenerative Changes and Neurovascular Damages
   Gabriela Dumitrita Stanciu et al, 2020, Journal of Clinical Medicine CrossRef
4. The many facets of CD26/dipeptidyl peptidase 4 and its inhibitors in disorders of the CNS – a critical overview
   Hans-Gert Bernstein et al, 2023, Reviews in the Neurosciences CrossRef
5. Antidiabetic treatment on memory and spatial learning: From the pancreas to the neuron
   Eleni Xourgia et al, 2019, World Journal of Diabetes CrossRef
6. Hotspots and frontier trends of diabetic associated cognitive decline research based on rat and mouse models from 2012 to 2021: A bibliometric study
   Jie Li et al, 2022, Frontiers in Neurology CrossRef
7. Role of Natural Polymers as Carriers for Targeting Cognitive Disorder
   null Bhavna et al, 2022, Polymeric Biomaterials and Bioengineering CrossRef
8. Dipeptidyl Peptidase-4 Inhibitors for the Potential Treatment of Brain Disorders; A Mini-Review With Special Focus on Linagliptin and Stroke
   Vladimer Darsalia et al, 2019, Frontiers in Neurology CrossRef
9. Pathophysiology Associated with Diabetes-induced Tauopathy and Development of Alzheimer’s Disease
   Debjeet Sur et al, 2023, Current Diabetes Reviews CrossRef